Steven Paulmeyer
Internal Medicine · Omaha, NENPI 1982041802
Payments from drug & device makers
Across 64 payments — averaging $17.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$365
- Pfizer$101
- Novartis$101
- Novo Nordisk$78
- Amgen$57
- E.r. Squibb & Sons, L.L.C.$43
- plus $351 from 14 others
What the payments were for
- Food & beverage$1,094100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 19 | $365 |
| Pfizer | 7 | $101 |
| Novartis | 6 | $101 |
| Novo Nordisk | 5 | $78 |
| Amgen | 4 | $57 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Insulet Corporation | 2 | $42 |
| Abbott | 2 | $38 |
| Merck | 2 | $33 |
| Valeritas, Inc. | 1 | $33 |
| Zealand Pharma US, Inc. | 2 | $29 |
| GSK | 2 | $29 |
| KCI USA, Inc. | 1 | $28 |
| Bayer | 2 | $27 |
| Boston Scientific | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
How this compares
$1,094 in reported general payments places this provider in the 80th percentile of 570 internal medicine providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 141 | $151,285 |
| XareltoRivaroxaban | 194 | $150,865 |
| OzempicSemaglutide | 127 | $123,483 |
| EliquisApixaban | 126 | $97,033 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 108 | $84,252 |
| AustedoDeutetrabenazine | 19 | $70,824 |
| FarxigaDapagliflozin Propanediol | 63 | $48,360 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 117 | $34,407 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $24,301 |
| MounjaroTirzepatide | 20 | $20,688 |
| MultaqDronedarone Hcl | 17 | $19,700 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 35 | $15,490 |
| MyrbetriqMirabegron | 39 | $14,638 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 67 | $14,003 |
| LinzessLinaclotide | 15 | $12,105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arexvy, Anoro Ellipta, Shingrix, Incruse Ellipta | $29 | $157,811352 claims |
| Johnson & JohnsonXarelto | $14 | $150,865194 claims |
| Novo NordiskOzempic | $78 | $123,483127 claims |
| PfizerEliquis | $101 | $97,033126 claims |
| Lilly USA, LLCMounjaro | $13 | $20,68820 claims |
| Sanofi-aventis U.S. LLCMultaq | $15 | $19,70017 claims |
| AbbVieLinzess | $365 | $12,10515 claims |
| MerckJanuvia | $33 | $9,52318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 570 internal medicine providers in Nebraska.
Other internal medicine in Omaha
- Michael DunnOmaha$7.9M
- Joel MichalskiOmaha$1.6M
- Ariana BauerOmaha$1.5M
- David CrockettOmaha$821K
- Bryant EnglandOmaha$637K
- Adam BurdorfOmaha$313K
- Brian BoerOmaha$142K
- David JasperOmaha$128K
- Andrew RorieOmaha$61K
- Mohamed AhmedOmaha$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.